Table 4.
Pharmacological interactions of the Tocilizumab, Ruxolitinib and colchicine with the most common antineoplastic drugs.
| Antineoplastic agents | Drug interaction with antiCOVID-19 agents | Mechanism of interaction |
|---|---|---|
| Abiraterone | Tocilizumab | Tocilizumab reduces abiraterone as a CYP3A4 inducer. |
| Coclchicine | Increase abiraterone as CYP3A4 inhibitor | |
| Alectinib | Ruxolitinib | Increased bradycardic effect. |
| Axitinib | Tocilizumab | Tocilizumab reduces axitinib as a CYP3A4 inducer. |
| Bosutinib | Tocilizumab | Tocilizumab reduces bosutinib as a CYP3A4 inducer. |
| Brigatinib | Ruxolitinib | Increased bradycardic effect. |
| Tocilizumab | Tocilizumab reduces brigatinib serum as a CYP3A4 inducer. | |
| Cabozantinib | Tocilizumab | Tocilizumab reduces cabozantinib as a CYP3A4 inducer. |
| Ceritinib | Colchicine | Increased colchicine serum concentration. |
| Ruxolitinib | Increased ruxolitinib serum concetration. | |
| Tocilizumab | Tocilizumab reduces ceritinib as a CYP3A4 inducer. | |
| Cisplatin | Colchicine | adjust doses because uricemia increases |
| Cobimetinib | Tocilizumab | Tocilizumab reduces cobimetinib, as a CYP3A4 inducer. |
| CPI | Ruxolitinib | Therapeutic effect reduction or synergism (nivolumab) |
| Baricitinib | Interference with pharmacodynamic activity and therapeutic efficacy of these molecules | |
| Tocilizumab | ||
| Crizotinib | Colchicine | Increased colchicine and |
| Ruxolitinib | increased bradycardic effect as CYP3A4 inhibitor | |
| Tocilizumab | Tocilizumab reduces crizotinib as a CYP3A4 inducer | |
| Dasatinib | Tocilizumab | Tocilizumab reduces dasatinib as a CYP3A4 inducer. |
| Docetaxel | Tocilizumab | Tocilizumab reduces docetaxel as a CYP3A4 inducer. |
| Coclchicine | Iincrease docetaxel as a CYP 3A4 inhibitor. | |
| Enzalutamide | Tocilizumab | Tocilizumab reduces enzalutamide as a CYP3A4 inducer. |
| Erlotinib | Tocilizumab | Tocilizumab reduces erlotinib as a CYP3A4 inducer. |
| Everolimus | Tocilizumab | Tocilizumab reduces serum concentration as a CYP3A4 inducer. |
| Fluorouracil | Tocilizumab (eculizumab) | Increased immunosuppressive action; |
| Fluorouracil-resistance inhibition | ||
| Exemestane | Tocilizumab | Tocilizumab reduces exemestane, as a CYP3A4 inducer. |
| Gefinitib | Tocilizumab | Tocilizumab reduces gefitinib as a CYP3A4 inducer. |
| Ibrutinib | Tocilizumab | Tocilizumab reduces ibrutinib as a CYP3A4 inducer. |
| Idelalisib | Tocilizumab | Tocilizumab reduces idelasib as a CYP3A4 inducer. |
| Ixazomib | Tocilizumab | Tocilizumab reduces ixazomib as a CYP3A4 inducer. |
| Lapatinib | Colchicine | Lapatinib increases colchicine as a glycoproteine-P, ABCB1 inhibitor. |
| Tocilizumab | Tocilizumab reduces lapatinib as a CYP3A4 inducer. | |
| Neratinib | Colchicine | Neratinib increases colchicine as glycoproteine-P ABCB1 inhibitor. |
| Tocilizumab | Tocilizumab reduces neratinib as a CYP3A4 inducer. | |
| Nilotinib | Colchicine | Nilotinib increases colchicine as a CYP 3A4 inhibitor. |
| Ruxolitinib | Nilotinib increases ruxolitinib as a CYP 3A4 inhibitor. | |
| Tocilizumab | Tocilizumab reduces nilotinib as a CYP3A4 inducer. | |
| Olaparib | Tocilizumab | Tocilizumab reduces olaparib as a CYP3A4 inducer. |
| Paclitaxel | Tocilizumab | Tocilizumab reduces paclitaxel serum as a CYP3A4 inducer |
| Palbociclib | Tocilizumab | Tocilizumab reduces palbociclib as a CYP3A4 inducer. |
| Panobinostat | Tocilizumab | Tocilizumab reduces panobinostat as a CYP3A4 inducer. |
| Pazopanib | Tocilizumab | Tocilizumab reduces pazopanib as a CYP3A4 inducer. |
| Pomalidomide | Tocilizumab | Increased immunosuppressive effect. |
| Regorafenib | Tocilizumab | Tocilizumab reduces regorafenib as a CYP3A4 inducer. |
| Ribociclib | Colchicine | Ribociclib increases colchicine as a CYP 3A4 inhibitor. |
| Ruxolitinib | Ribociclib increases colchicine as a CYP 3A4 inhibitor. | |
| Tocilizumab | Tocilizumab reduces ribociclib, as a CYP3A4 inducer. | |
| Ruxolitinib | Tocilizumab | Tocilizumab reduces ruxolitinib as a CYP3A4 inducer. |
| Sunitinib | Tocilizumab | Tocilizumab reduces sunitinib as a CYP3A4 inducer. |
| Tamoxifene | Colchicine | Tamoxifene increases colchicine as a glycoproteine-P, ABCB1 inhibitor. |
| Tocilizumab | Tocilizumab reduces tamoxifene as a CYP3A4 inducer. | |
| Vandetanib | Tocilizumab | Tocilizumab reduces vandetanib as a CYP3A4 inducer. |
| Venetoclax | Tocilizumab | Tocilizumab reduces venetoclax as a CYP3A4 inducer. |
| Alcaloids of the vinca | Colchicine | Synergy of action and enhancement of toxicity. |
CPI: Check Point inhibitors.